HKEX Announcement Insights | Yidu Tech Releases Annual Results, Reporting Shareholders' Attributable Profit of RMB 72.709 Million, Successfully Achieving a Historic Transition from Loss to Profit

Baoji Pharma-B (02659): The clinical trial application for BJ044 Injection (recombinant ulinastatin) has been approved by the National Medical Products Administration; Fibocom (00638) plans to acquire a 37.16% stake in Hangsheng Electronics for RMB 1.428 billion, achieving vertical integration of hardware and software combining 'communication modules + automotive electronics systems'.

Zhitong FinanceJun 29 21:07 ET

Selected HKEX Announcements | Oceanwide Holdings reported over 160% year-on-year revenue growth in the last fiscal year; TSUGAMI China posted annual profit exceeding HK$1 billion

① Oceanwide Holdings reported revenue growth of over 160% in the previous fiscal year—what was its scale? ② King Machine Tool (China) achieved annual profit exceeding HK$1 billion; what was its year-over-year growth rate?

cls.cnJun 29 09:11 ET

Medicine Mind Health (02138) announced its annual results, reporting a loss attributable to equity shareholders of approximately HK$403 million, an increase of about 1.41 times year-on-year.

Medicine Mind Health (02138) announced its annual results for the year ended March 31, 2026, reporting total revenue of approximately HK$3.77 billion, a year-on-year decrease of 8.9%; net loss attributable to equity shareholders of the company amounted to approximately HK$4.03 billion, an increase of about 141% year-on-year; and basic loss per share was HK$0.34.

Zhitong FinanceJun 29 07:12 ET

Express News | EC Healthcare FY Revenue HKD 3,770.2 Million

ReutersJun 29 07:06 ET

Express News | EC Healthcare FY Net Income Attributable HKD -402.7 Million

ReutersJun 29 07:05 ET

EC HEALTHCARE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2026

HKEXJun 29 07:04 ET · Announcements